Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a rare inflammatory disorder of the central nervous system (CNS) characterized by the presence of serum or cerebrospinal fluid (CSF) autoantibodies against myelin oligodendrocyte glycoprotein (MOG-IgG).
Date
2024-03
References
1. Marignier R, Hacohen Y, Cobo-Calvo A, et al. Myelin-oligodendrocyte glycoprotein antibodyassociated disease. Lancet Neurol 2021;20:762-772. 2. Hor JY, Fujihara K. Epidemiology of myelin oligodendrocyte glycoprotein antibody-associated disease: a review of prevalence and incidence worldwide. Front Neurol 2023;14:1260358. 3. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015;85:177-189. 4. Carnero Contentti E, Lopez PA, Pettinicchi JP, et al. What percentage of AQP4-ab-negative NMOSD patients are MOG-ab positive? A study from the Argentinean multiple sclerosis registry (RelevarEM). Mult Scler Relat Disord 2021;49:102742. 5. Hamid SHM, Whittam D, Mutch K, et al. What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients. J Neurol 2017;264:2088-2094.
Language
eng
Format
video/mp4
Type
Image/MovingImage
Source
2024 North American Neuro-Ophthalmology Society Annual Meeting
